Welcome to our dedicated page for Uniqure SEC filings (Ticker: QURE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The uniQure N.V. (QURE) SEC filings page on Stock Titan brings together the company’s regulatory disclosures from the U.S. Securities and Exchange Commission. As a Nasdaq Global Select Market issuer, uniQure files current reports on Form 8‑K, annual reports on Form 10‑K, and quarterly reports on Form 10‑Q that describe its gene therapy business, clinical programs, financial condition, and material agreements. These filings document the company’s work in hemophilia B, Huntington’s disease, refractory temporal lobe epilepsy, ALS, Fabry disease, and other severe conditions.
For uniQure, Form 8‑K filings are particularly important. They include clinical and regulatory updates on AMT‑130 for Huntington’s disease, such as topline Phase I/II data, details of pivotal trial design, and feedback from pre‑Biologics License Application meetings with the U.S. Food and Drug Administration. Other 8‑K reports describe public offerings of ordinary shares and pre‑funded warrants, amendments to senior secured term loan facilities with Hercules Capital, and the establishment of at‑the‑market equity programs. Filings also reference the company’s role in the multi‑year clinical development of a gene therapy for hemophilia B and its licensing arrangements with CSL.
On this page, investors can review uniQure’s SEC documents to understand how it reports results of operations, research and development spending, direct financial obligations, and other events that may affect QURE stock. Stock Titan enhances access to these filings with AI‑powered summaries that highlight key points from lengthy reports, helping readers quickly identify major clinical milestones, regulatory decisions, financing terms, and risk disclosures. Real‑time updates from EDGAR, along with structured access to items such as 8‑K current reports and other registered offerings, support deeper analysis of uniQure’s evolving gene therapy portfolio and capital structure.
uniQure N.V. Chief Financial Officer Christian Klemt reported an open-market sale of 6,217 ordinary shares of the company. The shares were sold at a weighted average price of $23.86 per share and were linked to the vesting of restricted share units.
According to the disclosure, the shares were sold solely to cover estimated withholding taxes under automatic sale instructions in the relevant restricted share unit agreement, meaning the transaction was not a discretionary trade by the executive. After this tax-related sale, Klemt still directly owns 211,513 ordinary shares.
uniQure N.V. (QURE) received an amended Schedule 13G/A showing that investment firm EcoR1 Capital, LLC, its fund EcoR1 Capital Fund Qualified, L.P., and Oleg Nodelman now report 0 ordinary shares beneficially owned, representing 0% of the class as of 12/31/2025.
All three reporting persons state they have no sole or shared voting or dispositive power over uniQure ordinary shares. They also indicate they own 5 percent or less of the class and disclaim group status and broader beneficial ownership beyond any pecuniary interest. The certifications emphasize that any securities were acquired and held in the ordinary course of business and not for the purpose of changing or influencing control of uniQure.
Avoro Capital Advisors LLC and Behzad Aghazadeh report beneficial ownership of 6,150,000 ordinary shares of uniQure N.V., equal to 9.87% of the company’s ordinary shares. This percentage is based on 62,291,663 shares outstanding as of November 6, 2025.
The shares were acquired solely for investment purposes on behalf of Avoro Life Sciences Fund LLC, with Aghazadeh acting as portfolio manager and controlling person of Avoro. The filers state the holdings are in the ordinary course of business and not for changing or influencing control of uniQure.
RTW Investments, LP and Roderick Wong, M.D. report a significant ownership stake in uniQure N.V. in this amended Schedule 13G filing. They disclose beneficial ownership of 3,711,462 ordinary shares, representing 6.0% of the class, based on 62,291,663 shares outstanding as of November 6, 2025.
The shares are held by RTW-managed funds, with RTW Investments and Dr. Wong sharing voting and dispositive power over the same 3,711,462 shares. They certify the position is held in the ordinary course of business and not for the purpose of changing or influencing control of uniQure.
uniQure N.V. received a Schedule 13G reporting that a group of affiliated Susquehanna entities collectively beneficially owns 3,536,485 ordinary shares, or 5.7% of the company’s outstanding stock. The group includes G1 Execution Services, SIG Brokerage, Susquehanna Portfolio Strategies and Susquehanna Securities.
Their holdings include options to buy 31,000 shares at SIG Brokerage and 2,251,400 shares at Susquehanna Securities. Based on the company’s Form 10-Q, there were 62,291,663 ordinary shares outstanding as of November 6, 2025. The filing states the securities were acquired and are held in the ordinary course of business, not to change or influence control of uniQure.
State Street Corporation has disclosed beneficial ownership of uniQure common stock. It reports holding 3,231,043 shares of uniQure N.V. common stock, representing 5.2% of the class as of 12/31/2025.
State Street reports shared voting power over 3,194,147 shares and shared dispositive power over 3,231,043 shares, with no sole voting or dispositive power. The position is certified as being held in the ordinary course of business and not for the purpose of changing or influencing control of uniQure.
uniQure N.V. (QURE) received an updated ownership report from Aberdeen Group plc and abrdn Inc. The firms report beneficial ownership of 3,678,640 ordinary shares, representing 5.91% of uniQure’s outstanding ordinary shares.
The shares are held with shared power to vote and dispose, and no sole voting or dispositive power. The reporting parties state the holdings are maintained in the ordinary course of business and not for the purpose of changing or influencing control of uniQure.
uniQure director Robert Gut reported option exercises and share sales in the company’s ordinary shares. On January 12, 2026, he exercised a stock option for 17,810 ordinary shares at $14.08 per share, converting derivative securities into directly held stock.
On the same date, he sold ordinary shares in several transactions: 17,310 shares at a weighted average price of $24.39 (with individual sale prices between $24.02 and $25.00), 500 shares at a weighted average price of $25.03 (with prices between $25.02 and $25.04), and 7,803 shares at $25.09. After these trades, he directly owned 32,342 ordinary shares. All transactions were carried out under a Rule 10b5-1 trading plan adopted on July 8, 2025.